Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
WYTENSIN (guanabenz acetate) is an oral antihypertensive agent approved in 1982 that works as a centrally-acting alpha-2 adrenergic agonist to lower blood pressure. It is used for management of hypertension, typically in patients who require additional blood pressure control beyond first-line agents. The drug reduces sympathetic outflow from the central nervous system to achieve its antihypertensive effect.
With LOE approaching and minimal current linked job activity, this product is in managed decline with a small, lean team focused on maximizing remaining exclusivity and transitioning to generic competition.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on WYTENSIN offers limited career growth potential given its approaching loss of exclusivity and minimal hiring activity (0 linked jobs). Roles available are primarily defensive in nature—focused on managing decline, maintaining compliance, and supporting the transition to generic competition rather than driving innovation or market expansion.
Worked on WYTENSIN at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.